

To become certified to prescribe BLENREP, you must review the BLENREP Prescribing Information, **Program Overview**, and **Education Program for Prescribers** and successfully complete and submit this **Knowledge Assessment** and the **Prescriber Enrollment Form**.

Go to www.BLENREPREMS.com and register to complete this Knowledge Assessment online or fax the completed form to 1-888-635-1044.

You must answer ALL 8 questions correctly on this assessment.

Once both the **Knowledge Assessment** and **Prescriber Enrollment Form** are completed, the BLENREP REMS will send confirmation of your certification, including your assigned BLENREP REMS identification number, to the email provided on the enrollment form within 2 business days. If you did not answer all questions on the **Knowledge Assessment** correctly, the BLENREP REMS will provide instructions on how to retake your **Knowledge Assessment**.

(Fields marked with an * are REQUIRED)

Prescriber Information	
*First Name	*Last Name
*National Provider Identifier (NPI)#	
*Office Phone Number	*Email

ASSESSMENT QUESTIONS

1. While on treatment with BLENREP, patients are at risk of experiencing ocular toxicity, such as:
 - Corneal exam findings
 - Reduction in best-corrected visual acuity (BCVA)
 - Blurred vision
 - Dry eye
 - All of the above
2. Before starting a patient on BLENREP, I must counsel patients on the following:
 - The risk of ocular toxicity
 - The need for monitoring via ophthalmic exams
 - To inform their healthcare provider of any ocular symptoms
 - All of the above
3. While treating patients with BLENREP, I should counsel patients:
 - They may experience loss of sense of smell
 - To use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy
 - To not eat grapefruit while taking BLENREP
 - BLENREP is for home administration

BLENREP REMS Knowledge Assessment (continued)

4. Eighty-three percent of patients required a dosage modification of BLENREP for ocular toxicity based on ophthalmic exam findings or other ocular adverse reactions as defined by the Common Terminology Criteria for Adverse Events (CTCAE).
- True
 - False
5. Prescribers ensure ophthalmic exams are conducted by an eye care professional, such as an ophthalmologist or optometrist, per the following:
- Once annually
 - Before the first dose of BLENREP and for worsening symptoms
 - At baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated
 - None of the above
6. Before initiating treatment with BLENREP, I must enroll my patients in the REMS.
- True
 - False
7. How can the eye care professional provide prescribers the completed **Eye Care Professional Exam Form** before each dose?
- Fax/e-Fax
 - Patient
 - Adapted into healthcare technology
 - All of the above
8. Before each dose, I must submit the **Patient Status Form** to the REMS, confirming I assessed the patient's ophthalmic exam findings and authorized treatment.
- True
 - False

Trademarks are owned by or licensed to the GSK group of companies.

US-BLM-LTR-250006
0002-0039-56
REMS-102025

